The pharmaceutical industry is well-positioned to witness solid long-term growth thanks to the fast-expanding market for drugs and therapies. Moreover, given the consistent product demand, the pharma business is less susceptible to economic cycles.
Given the uncertainties surrounding the economy and the industry’s solid long-term growth prospects, investors could consider buying fundamentally strong pharma stocks GSK plc (GSK), Horizon Therapeutics Public Limited Company (HZNP), and Neurocrine Biosciences, Inc. (NBIX), which appear undervalued compared to their peers.
